Stocks in Focus: Clean Energy Fuels Corp. (NASDAQ:CLNE), Quicksilver Resources Inc (NYSE:KWK), Sinovac Biotech Ltd.(NASDAQ:SVA)

Dallas, TX -- (SBWIRE) -- 03/15/2013 -- Marketbuzzreport.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Clean Energy Fuels Corp. (NASDAQ:CLNE) shares climbed 5.46% and closed at $14.48. Research analysts at Ascendiant Capital Markets began coverage on shares of CLNE in a report released on Mar. 11. The firm set a “buy” rating and a $15.50 price target on the stock.

Additionally, the company, on Feb. 28, reported a fourth quarter loss of $41.7 million or $0.46 per share, from $20.9 million or $0.29 per share last year. Adjusted net loss for the quarter was $0.23 per share, compared to $0.21 per share in the same quarter last year. Meanwhile, revenue for the quarter rose to $99.1 million, from $86.2 million in the fourth quarter prior year. Analysts expected the company to report a loss of $0.22 per share on revenues of $91.53 million for the quarter.

Get Latest News, Updates on CLNE Here

Quicksilver Resources Inc (NYSE:KWK) stock climbed 26.85% to $2.74. McNicoll Lewis & Vlak downgraded shares of Quicksilver Resources from a buy rating to a hold rating in a research note released on Mar. 11.

Additionally, the company, on Feb. 25, reported a fourth quarter loss of $1.10 billion or $6.47 per share, versus net income of $23.53 million or $0.14 per share in the same period last year. Adjusted net loss for the quarter was $2.39 million or $0.01 per share. Meanwhile, revenues for the three-month period dipped to $179.07 million from $223.09 million in the same quarter a year earlier. Analysts expected the company to report earnings of $0.01 per share on revenues of $168.69 million for the quarter.

Is KWK a Strong Buying Opportunity After The Recent Slump? Find out Here

Sinovac Biotech Ltd.(NASDAQ:SVA) shares climbed 17.87% to $3.76. The company, on Mar. 14, announced preliminary top-line data from its Phase III clinical trial assessing the efficacy, immunogenicity and safety of the Company's proprietary Enterovirus 71 ("EV71") vaccine against hand, foot and mouth disease ("HFMD"). The primary objective of the study was to evaluate the efficacy of the EV71 vaccine in the prevention of HFMD caused by EV71 in infants of 6 to 35 months old.

Is SVA Signaling a Buy After The Sudden Gain? Don’t Miss Out Free Trend Analysis Here

About Marketbuzzreport.com
Marketbuzzreport.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Marketbuzzreport.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.marketbuzzreport.com

Disclaimer
The assembled information disseminated by Marketbuzzreport.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Marketbuzzreport.com does expect that investors will buy and sell securities based on information assembled and presented in Marketbuzzreport.com. PLEASE always do your own due diligence, and consult your financial advisor.